Courtney D. Dinardo

Hematology
1515 Holcombe Blvd Unit 428
Houston, TX 77030

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 600 publications

FLT3-directed therapy in acute myeloid leukemia: lessons from the final analysis of LACEWING.

FLT3-directed therapy in acute myeloid leukemia: lessons from the final analysis of LACEWING.

Journal: Haematologica
Published: August 13, 2026

Erratum: Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Erratum: Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 27, 2026

Erratum: All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE).

Erratum: All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 23, 2026

Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 02, 2026

All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE).

All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 11, 2026

All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia.

All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia.

Journal: The New England journal of medicine
Published: June 03, 2026

A quantitative definition of the clinical manifestations of GATA2 deficiency in adults.

A quantitative definition of the clinical manifestations of GATA2 deficiency in adults.

Journal: Blood
Published: May 18, 2026

p53 Immunohistochemistry Is a Reliable Method for Assessing TP53 Allelic and Functional Status in TP53-Mutated Cases.

p53 Immunohistochemistry Is a Reliable Method for Assessing TP53 Allelic and Functional Status in TP53-Mutated Cases.

Journal: American journal of hematology
Published: May 14, 2026

Final results of a phase II study of the combination of azacitidine and ruxolitinib in patients with myelofibrosis.

Final results of a phase II study of the combination of azacitidine and ruxolitinib in patients with myelofibrosis.

Journal: Haematologica
Published: May 04, 2026

Mutational profiling in acute myeloid leukemia.

Mutational profiling in acute myeloid leukemia.

Journal: Haematologica
Published: May 01, 2026

Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemia.

Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemia.

Journal: Haematologica
Published: April 22, 2026

The Role of Advanced Molecular Diagnostics in Informing Targeted Therapies for AML.

The Role of Advanced Molecular Diagnostics in Informing Targeted Therapies for AML.

Journal: Human pathology
Published: April 20, 2026
Showing 1-12 of 600

Last Updated: 09/26/2026